{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:48:01Z","timestamp":1791776881490,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["MSGP NETH-15-01"],"award-info":[{"award-number":["MSGP NETH-15-01"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["CVAL489ANL08"],"award-info":[{"award-number":["CVAL489ANL08"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12882-017-0789-x","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T12:24:13Z","timestamp":1513772653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels"],"prefix":"10.1186","volume":"18","author":[{"name":"Holland Nephrology Study (HONEST) Network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Gant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozewijn D.","family":"Laverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liffert","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje C. J.","family":"Slagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Waanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Hemmelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerjan","family":"Navis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"issue":"1","key":"789_CR1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","volume":"21","author":"RJ Hene","year":"1982","unstructured":"Hene RJ, Boer P, Koomans HA, Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982;21(1):98\u2013101.","journal-title":"Kidney Int"},{"issue":"10","key":"789_CR2","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","volume":"112","author":"M Quinkler","year":"2005","unstructured":"Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M, Stewart PM. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation. 2005;112(10):1435\u201343.","journal-title":"Circulation"},{"key":"789_CR3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2369-15-44","volume":"15","author":"A Hannemann","year":"2014","unstructured":"Hannemann A, Rettig R, Dittmann K, Volzke H, Endlich K, Nauck M, Wallaschofski H. Aldosterone and glomerular filtration--observations in the general population. BMC Nephrol. 2014;15:44.","journal-title":"BMC Nephrol"},{"issue":"1","key":"789_CR4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0300-8932(10)70015-4","volume":"63","author":"J Roldan","year":"2010","unstructured":"Roldan J, Morillas P, Castillo J, Andrade H, Guillen S, Nunez D, Quiles J, Bertomeu V. Plasma aldosterone and glomerular filtration in hypertensive patients with preserved renal function. Rev Esp Cardiol. 2010;63(1):103\u20136.","journal-title":"Rev Esp Cardiol"},{"key":"789_CR5","doi-asserted-by":"crossref","unstructured":"Ritz E, Tomaschitz A. Aldosterone and kidney: a rapidly moving frontier (an update). Nephrol Dial Transplant. 2013;","DOI":"10.1093\/ndt\/gft035"},{"issue":"3","key":"789_CR6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MED.0b013e328360c200","volume":"20","author":"JS Williams","year":"2013","unstructured":"Williams JS. Evolving research in nongenomic actions of aldosterone. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):198\u2013203.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"789_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-3-319-09162-4_5","volume-title":"Cardio-renal clinical challenges","author":"CM Gant","year":"2015","unstructured":"Gant CM, Laverman GD, Navis GJ. MRA inhibition in CKD: more than salt and water. In: Goldsmith D, Covic A, Spaak J, editors. Cardio-renal clinical challenges. Switzerland: Springer International Publishing; 2015. p. 41\u201350."},{"issue":"5","key":"789_CR8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","volume":"63","author":"LA Inker","year":"2014","unstructured":"Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"789_CR9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","volume":"19","author":"L Vogt","year":"2008","unstructured":"Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol. 2008;19(5):999\u20131007.","journal-title":"J Am Soc Nephrol"},{"key":"789_CR10","doi-asserted-by":"crossref","first-page":"d4366","DOI":"10.1136\/bmj.d4366","volume":"343","author":"MC Slagman","year":"2011","unstructured":"Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, Navis G, Laverman GD, HOlland NEphrology STudy Group. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.","journal-title":"BMJ"},{"issue":"2","key":"789_CR11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.HYP.5.2.244","volume":"5","author":"FH Derkx","year":"1983","unstructured":"Derkx FH, Tan-Tjiong L, Wenting GJ, Boomsma F, Man in \u2018t Veld AJ, Schalekamp MA. Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension. 1983;5(2):244\u201356.","journal-title":"Hypertension"},{"issue":"6","key":"789_CR12","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/ndt\/gft007","volume":"28","author":"EP McQuarrie","year":"2013","unstructured":"McQuarrie EP, Freel EM, Mark PB, Fraser R, Connell JM, Jardine AG. Urinary sodium excretion is the main determinant of mineralocorticoid excretion rates in patients with chronic kidney disease. Nephrol Dial Transplant. 2013;28(6):1526\u201332.","journal-title":"Nephrol Dial Transplant"},{"key":"789_CR13","first-page":"CD007004","volume":"4","author":"D Bolignano","year":"2014","unstructured":"Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"789_CR14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159\u201364.","journal-title":"Arch Intern Med"},{"issue":"10008","key":"789_CR15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368.","journal-title":"Lancet"},{"issue":"11","key":"789_CR16","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1210\/jc.2007-1088","volume":"92","author":"R Bentley-Lewis","year":"2007","unstructured":"Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab. 2007;92(11):4472\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"789_CR17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJM198104163041602","volume":"304","author":"ML Tuck","year":"1981","unstructured":"Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304(16):930\u20133.","journal-title":"N Engl J Med"},{"issue":"9","key":"789_CR18","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM198908313210905","volume":"321","author":"AP Rocchini","year":"1989","unstructured":"Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321(9):580\u20135.","journal-title":"N Engl J Med"},{"issue":"4","key":"789_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ajh\/hpw003","volume":"29","author":"W Kawarazaki","year":"2016","unstructured":"Kawarazaki W, Fujita T. The role of Aldosterone in obesity-related hypertension. Am J Hypertens. 2016;29(4):415\u201323.","journal-title":"Am J Hypertens"},{"issue":"9","key":"789_CR20","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2010121251","volume":"22","author":"MH de Borst","year":"2011","unstructured":"de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011;22(9):1603\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"789_CR21","doi-asserted-by":"crossref","first-page":"H1504","DOI":"10.1152\/ajpheart.00331.2014","volume":"307","author":"M Imazu","year":"2014","unstructured":"Imazu M, Takahama H, Asanuma H, Funada A, Sugano Y, Ohara T, Hasegawa T, Asakura M, Kanzaki H, Anzai T, Kitakaze M. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. Am J Physiol Heart Circ Physiol. 2014;307(10):H1504\u201311.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"789_CR22","doi-asserted-by":"crossref","first-page":"F1088","DOI":"10.1152\/ajprenal.00474.2004","volume":"289","author":"T Shimada","year":"2005","unstructured":"Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289(5):F1088\u201395.","journal-title":"Am J Physiol Renal Physiol"},{"key":"789_CR23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ijcard.2015.03.062","volume":"184","author":"A Tomaschitz","year":"2015","unstructured":"Tomaschitz A, Pilz S, Rus-Machan J, Meinitzer A, Brandenburg VM, Scharnagl H, Kapl M, Grammer T, Ritz E, Horina JH, Kleber ME, Pieske B, Kraigher-Krainer E, Hartaigh BO, Toplak H, van Ballegooijen AJ, Amrein K, Fahrleitner-Pammer A, Marz W. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. Int J Cardiol. 2015;184:710\u20136.","journal-title":"Int J Cardiol"},{"issue":"3","key":"789_CR24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1161\/HYPERTENSIONAHA.111.173948","volume":"58","author":"C Maniero","year":"2011","unstructured":"Maniero C, Fassina A, Guzzardo V, Lenzini L, Amadori G, Pelizzo MR, Gomez-Sanchez C, Rossi GP. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension. 2011;58(3):341\u20136.","journal-title":"Hypertension"},{"issue":"2","key":"789_CR25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1152\/physrev.00030.2003","volume":"84","author":"A Spat","year":"2004","unstructured":"Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84(2):489\u2013539.","journal-title":"Physiol Rev"},{"issue":"9","key":"789_CR26","first-page":"14625","volume":"8","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Feng B. Association of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysis. Int J Clin Exp Med. 2015;8(9):14625\u201333.","journal-title":"Int J Clin Exp Med"},{"issue":"5","key":"789_CR27","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1681\/ASN.2006060554","volume":"18","author":"T Yamamoto","year":"2007","unstructured":"Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, Kato A, Nakamura Y, Suzuki F, Hishida A. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007;18(5):1558\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"789_CR28","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/HJH.0b013e328354f65b","volume":"30","author":"S Terata","year":"2012","unstructured":"Terata S, Kikuya M, Satoh M, Ohkubo T, Hashimoto T, Hara A, Hirose T, Obara T, Metoki H, Inoue R, Asayama K, Kanno A, Totsune K, Hoshi H, Satoh H, Sato H, Imai Y. Plasma renin activity and the aldosterone-to-renin ratio are associated with the development of chronic kidney disease: the Ohasama study. J Hypertens. 2012;30(8):1632\u20138.","journal-title":"J Hypertens"},{"issue":"12","key":"789_CR29","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2010010085","volume":"21","author":"CS Fox","year":"2010","unstructured":"Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol. 2010;21(12):2143\u20139.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-017-0789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T02:49:12Z","timestamp":1693363752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-017-0789-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1186\/s12882-017-0789-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"370"}}